BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 17875788)

  • 1. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
    Rowinsky EK; Youssoufian H; Tonra JR; Solomon P; Burtrum D; Ludwig DL
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5549s-5555s. PubMed ID: 17875788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
    Burtrum D; Zhu Z; Lu D; Anderson DM; Prewett M; Pereira DS; Bassi R; Abdullah R; Hooper AT; Koo H; Jimenez X; Johnson D; Apblett R; Kussie P; Bohlen P; Witte L; Hicklin DJ; Ludwig DL
    Cancer Res; 2003 Dec; 63(24):8912-21. PubMed ID: 14695208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-like growth factor-I receptor signaling blockade combined with radiation.
    Allen GW; Saba C; Armstrong EA; Huang SM; Benavente S; Ludwig DL; Hicklin DJ; Harari PM
    Cancer Res; 2007 Feb; 67(3):1155-62. PubMed ID: 17283150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
    Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
    Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
    Yeh J; Litz J; Hauck P; Ludwig DL; Krystal GW
    Lung Cancer; 2008 May; 60(2):166-74. PubMed ID: 18006183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.
    Attias-Geva Z; Bentov I; Ludwig DL; Fishman A; Bruchim I; Werner H
    Eur J Cancer; 2011 Jul; 47(11):1717-26. PubMed ID: 21450456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871.
    Cohen BD; Baker DA; Soderstrom C; Tkalcevic G; Rossi AM; Miller PE; Tengowski MW; Wang F; Gualberto A; Beebe JS; Moyer JD
    Clin Cancer Res; 2005 Mar; 11(5):2063-73. PubMed ID: 15756033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review.
    Ozkan EE
    Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer.
    Sachdev D; Singh R; Fujita-Yamaguchi Y; Yee D
    Cancer Res; 2006 Feb; 66(4):2391-402. PubMed ID: 16489046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
    Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
    Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction and characterization of single-chain antibodies against human insulin-like growth factor-I receptor from hybridomas producing 1H7 or 3B7 monoclonal antibody.
    Kusada Y; Morizono T; Matsumoto-Takasaki A; Sakai K; Sato S; Asanuma H; Takayanagi A; Fujita-Yamaguchi Y
    J Biochem; 2008 Jan; 143(1):9-19. PubMed ID: 17956902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation.
    Maloney EK; McLaughlin JL; Dagdigian NE; Garrett LM; Connors KM; Zhou XM; Blättler WA; Chittenden T; Singh R
    Cancer Res; 2003 Aug; 63(16):5073-83. PubMed ID: 12941837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo.
    Ye JJ; Liang SJ; Guo N; Li SL; Wu AM; Giannini S; Sachdev D; Yee D; Brünner N; Ikle D; Fujita-Yamaguchi Y
    Horm Metab Res; 2003; 35(11-12):836-42. PubMed ID: 14710366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of antibody-mediated insulin-like growth factor I receptor (IGF-IR) down-regulation in MCF-7 breast cancer cells.
    Ohtani M; Numazaki M; Yajima Y; Fujita-Yamaguchi Y
    Biosci Trends; 2009 Aug; 3(4):131-8. PubMed ID: 20103837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
    Rowinsky EK; Schwartz JD; Zojwalla N; Youssoufian H; Fox F; Pultar P; Novosyadlyy R; Cosaert J; Ludwig DL
    Curr Drug Targets; 2011 Dec; 12(14):2016-33. PubMed ID: 21777192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
    Tonra JR; Corcoran E; Deevi DS; Steiner P; Kearney J; Li H; Ludwig DL; Zhu Z; Witte L; Surguladze D; Hicklin DJ
    Anticancer Res; 2009 Jun; 29(6):1999-2007. PubMed ID: 19528458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy.
    Adachi Y; Lee CT; Carbone DP
    Novartis Found Symp; 2004; 262():177-89; discussion 190-2, 265-8. PubMed ID: 15562829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralising activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors.
    Pandini G; Wurch T; Akla B; Corvaia N; Belfiore A; Goetsch L
    Eur J Cancer; 2007 May; 43(8):1318-27. PubMed ID: 17451939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of an antibody that can detect an activated IGF-I receptor in human cancers.
    Rubini M; D'Ambrosio C; Carturan S; Yumet G; Catalano E; Shan S; Huang Z; Criscuolo M; Pifferi M; Baserga R
    Exp Cell Res; 1999 Aug; 251(1):22-32. PubMed ID: 10438568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.